QQQ   354.00 (-0.25%)
AAPL   177.77 (-1.01%)
MSFT   333.91 (-0.60%)
META   272.45 (+0.39%)
GOOGL   126.17 (+0.13%)
AMZN   125.59 (+0.23%)
TSLA   213.80 (-1.75%)
NVDA   390.69 (-0.26%)
NIO   7.58 (-1.17%)
BABA   84.07 (-0.39%)
AMD   121.12 (+2.70%)
T   15.47 (+0.52%)
F   12.57 (-0.16%)
MU   67.49 (-0.41%)
CGC   0.72 (-7.66%)
GE   105.34 (+1.19%)
DIS   92.31 (+1.44%)
AMC   4.58 (-1.08%)
PFE   38.47 (-0.47%)
PYPL   64.73 (+0.34%)
NFLX   400.58 (-0.73%)
QQQ   354.00 (-0.25%)
AAPL   177.77 (-1.01%)
MSFT   333.91 (-0.60%)
META   272.45 (+0.39%)
GOOGL   126.17 (+0.13%)
AMZN   125.59 (+0.23%)
TSLA   213.80 (-1.75%)
NVDA   390.69 (-0.26%)
NIO   7.58 (-1.17%)
BABA   84.07 (-0.39%)
AMD   121.12 (+2.70%)
T   15.47 (+0.52%)
F   12.57 (-0.16%)
MU   67.49 (-0.41%)
CGC   0.72 (-7.66%)
GE   105.34 (+1.19%)
DIS   92.31 (+1.44%)
AMC   4.58 (-1.08%)
PFE   38.47 (-0.47%)
PYPL   64.73 (+0.34%)
NFLX   400.58 (-0.73%)
QQQ   354.00 (-0.25%)
AAPL   177.77 (-1.01%)
MSFT   333.91 (-0.60%)
META   272.45 (+0.39%)
GOOGL   126.17 (+0.13%)
AMZN   125.59 (+0.23%)
TSLA   213.80 (-1.75%)
NVDA   390.69 (-0.26%)
NIO   7.58 (-1.17%)
BABA   84.07 (-0.39%)
AMD   121.12 (+2.70%)
T   15.47 (+0.52%)
F   12.57 (-0.16%)
MU   67.49 (-0.41%)
CGC   0.72 (-7.66%)
GE   105.34 (+1.19%)
DIS   92.31 (+1.44%)
AMC   4.58 (-1.08%)
PFE   38.47 (-0.47%)
PYPL   64.73 (+0.34%)
NFLX   400.58 (-0.73%)
QQQ   354.00 (-0.25%)
AAPL   177.77 (-1.01%)
MSFT   333.91 (-0.60%)
META   272.45 (+0.39%)
GOOGL   126.17 (+0.13%)
AMZN   125.59 (+0.23%)
TSLA   213.80 (-1.75%)
NVDA   390.69 (-0.26%)
NIO   7.58 (-1.17%)
BABA   84.07 (-0.39%)
AMD   121.12 (+2.70%)
T   15.47 (+0.52%)
F   12.57 (-0.16%)
MU   67.49 (-0.41%)
CGC   0.72 (-7.66%)
GE   105.34 (+1.19%)
DIS   92.31 (+1.44%)
AMC   4.58 (-1.08%)
PFE   38.47 (-0.47%)
PYPL   64.73 (+0.34%)
NFLX   400.58 (-0.73%)
NASDAQ:TVTX

Travere Therapeutics (TVTX) Competitors

$19.18
+0.37 (+1.97%)
(As of 09:58 AM ET)
Compare
Today's Range
$18.85
$19.20
50-Day Range
$15.65
$22.89
52-Week Range
$14.51
$29.14
Volume
29,888 shs
Average Volume
1.44 million shs
Market Capitalization
$1.43 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.85

TVTX vs. CPRX, LGND, BMEA, IDYA, CRNX, CTIC, ETNB, PLRX, MNKD, and ARVN

Should you be buying Travere Therapeutics stock or one of its competitors? The main competitors of Travere Therapeutics include Catalyst Pharmaceuticals (CPRX), Ligand Pharmaceuticals (LGND), Biomea Fusion (BMEA), IDEAYA Biosciences (IDYA), Crinetics Pharmaceuticals (CRNX), CTI BioPharma (CTIC), 89bio (ETNB), Pliant Therapeutics (PLRX), MannKind (MNKD), and Arvinas (ARVN). These companies are all part of the "pharmaceutical preparations" industry.

Travere Therapeutics vs.

Catalyst Pharmaceuticals (NASDAQ:CPRX) and Travere Therapeutics (NASDAQ:TVTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, community ranking, institutional ownership, valuation, risk, analyst recommendations and earnings.

In the previous week, Catalyst Pharmaceuticals had 4 more articles in the media than Travere Therapeutics. MarketBeat recorded 17 mentions for Catalyst Pharmaceuticals and 13 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 0.34 beat Catalyst Pharmaceuticals' score of 0.18 indicating that Travere Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Catalyst Pharmaceuticals
7 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Travere Therapeutics
2 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Catalyst Pharmaceuticals currently has a consensus price target of $21.50, indicating a potential upside of 86.31%. Travere Therapeutics has a consensus price target of $30.85, indicating a potential upside of 63.99%. Given Catalyst Pharmaceuticals' higher probable upside, equities analysts clearly believe Catalyst Pharmaceuticals is more favorable than Travere Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Catalyst Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75
Travere Therapeutics
0 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.82

Catalyst Pharmaceuticals has higher revenue and earnings than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Catalyst Pharmaceuticals$214.20 million5.72$83.08 million$0.8813.11
Travere Therapeutics$212.02 million6.62-$278.48 million-$4.44-4.24

Catalyst Pharmaceuticals has a net margin of 38.76% compared to Travere Therapeutics' net margin of -130.98%. Catalyst Pharmaceuticals' return on equity of 34.72% beat Travere Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Catalyst Pharmaceuticals 38.76% 34.72% 28.75%
Travere Therapeutics -130.98% -236.09% -38.69%

86.7% of Catalyst Pharmaceuticals shares are owned by institutional investors. 14.1% of Catalyst Pharmaceuticals shares are owned by insiders. Comparatively, 4.7% of Travere Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Catalyst Pharmaceuticals received 431 more outperform votes than Travere Therapeutics when rated by MarketBeat users. Likewise, 74.88% of users gave Catalyst Pharmaceuticals an outperform vote while only 46.25% of users gave Travere Therapeutics an outperform vote.

CompanyUnderperformOutperform
Catalyst PharmaceuticalsOutperform Votes
468
74.88%
Underperform Votes
157
25.12%
Travere TherapeuticsOutperform Votes
37
46.25%
Underperform Votes
43
53.75%

Catalyst Pharmaceuticals has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500. Comparatively, Travere Therapeutics has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500.

Summary

Catalyst Pharmaceuticals beats Travere Therapeutics on 14 of the 18 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TVTX vs. The Competition

MetricTravere TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.40B$5.48B$4.53B$6.26B
Dividend YieldN/A2.53%6.05%6.50%
P/E Ratio-4.249.15130.6914.41
Price / Sales6.62328.023,483.2088.34
Price / CashN/A20.5022.2723.57
Price / Book28.074.774.655.43
Net Income-$278.48M$145.54M$116.46M$192.41M
7 Day Performance14.56%3.81%2.19%2.14%
1 Month Performance11.96%2.03%1.52%3.55%
1 Year Performance-22.43%19.41%13.19%1.25%

Travere Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CPRX
Catalyst Pharmaceuticals
2.8421 of 5 stars
$11.55
+0.4%
$21.50
+86.1%
+56.8%$1.23B$214.20M13.1376
LGND
Ligand Pharmaceuticals
2.6167 of 5 stars
$69.53
-3.6%
$101.67
+46.2%
-16.4%$1.20B$196.24M55.18154
BMEA
Biomea Fusion
1.4355 of 5 stars
$33.86
+7.7%
$40.29
+19.0%
+603.0%$1.20BN/A-10.5551
IDYA
IDEAYA Biosciences
2.1221 of 5 stars
$21.86
-1.6%
$29.40
+34.5%
+105.0%$1.25B$47.45M-14.3881
CRNX
Crinetics Pharmaceuticals
2.1715 of 5 stars
$22.05
-0.2%
$45.50
+106.3%
+18.4%$1.19B$4.29M-6.72143Positive News
CTIC
CTI BioPharma
2.1406 of 5 stars
$9.02
-0.3%
$10.29
+14.0%
+57.4%$1.19B$53M-15.5522Analyst Report
ETNB
89bio
2.0853 of 5 stars
$17.28
-2.3%
$34.00
+96.8%
+433.1%$1.26BN/A-6.1341Insider Selling
Positive News
PLRX
Pliant Therapeutics
2.3981 of 5 stars
$21.30
-0.9%
$47.83
+124.6%
+255.5%$1.26B$9.69M-7.4591
MNKD
MannKind
1.7605 of 5 stars
$4.43
-2.4%
$6.50
+46.7%
-6.3%$1.17B$99.77M-15.82348
ARVN
Arvinas
1.8915 of 5 stars
$21.90
-3.9%
$67.33
+207.5%
-47.7%$1.17B$137.40M-3.87280Positive News

Related Companies and Tools

This page (NASDAQ:TVTX) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -